ISAL 2023 | ADMIRAL update: co-occurrence of DNMT3A, NPM1 & FLT3 mutations in patients treated with gilteritinib
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, shares updates from the ADMIRAL trial (NCT02421939) that compared gilteritinib to salvage chemotherapy in patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). The trial reported that long-term survivors were almost exclusively patients who were bridged to an allogeneic transplant. In addition, a subset of patients carrying mutations in DNMT3A, NPM1, and FLT3 was found to have a high and durable response to gilteritinib. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
